(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.
Identifieur interne : 001023 ( Main/Exploration ); précédent : 001022; suivant : 001024(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.
Auteurs : RBID : pubmed:22518302Abstract
The aim of this study is to investigate whether (111)Indium-labelled recombinant FVIIa (rFVIIa) could be a potential radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with (111)In chloride. In vitro binding efficiency of (111)In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buffer, while it was 88-82% in serum. The binding efficiency of (111)In-DTPA-rFVIIa to TF (1-209)-sepharose was 48% in buffer whereas 39%-36% in serum, respectively. In vivo experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6-1.8 MBq (111)In-DTPA-rFVIIa up to 120-130 min. Five min after administration of (111)In-DTPA-rFVIIa, percentage of (111)In activity was 6.0% in the cardiac region and 24.5% in the liver region. After 2 hours activity was decreased to 3.3% in heart while it had increased to 42.0% in the liver. The (111)In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with significant TF expression such as acute bleeding lesions in the gastrointestinal tract.
DOI: 10.1155/2012/464810
PubMed: 22518302
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.</title><author><name sortKey="Nalla, Amarnadh" uniqKey="Nalla A">Amarnadh Nalla</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK-2200, Copenhagen</wicri:regionArea></affiliation></author><author><name sortKey="Buch, Inge" uniqKey="Buch I">Inge Buch</name></author><author><name sortKey="Sigvardt, Maibritt" uniqKey="Sigvardt M">Maibritt Sigvardt</name></author><author><name sortKey="Bodholdt, Rasmus Poul" uniqKey="Bodholdt R">Rasmus Poul Bodholdt</name></author><author><name sortKey="Kjaer, Andreas" uniqKey="Kjaer A">Andreas Kjaer</name></author><author><name sortKey="Hesse, Birger" uniqKey="Hesse B">Birger Hesse</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1155/2012/464810</idno><idno type="RBID">pubmed:22518302</idno><idno type="pmid">22518302</idno><idno type="wicri:Area/Main/Corpus">000D65</idno><idno type="wicri:Area/Main/Curation">000D65</idno><idno type="wicri:Area/Main/Exploration">001023</idno></publicationStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study is to investigate whether (111)Indium-labelled recombinant FVIIa (rFVIIa) could be a potential radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with (111)In chloride. In vitro binding efficiency of (111)In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buffer, while it was 88-82% in serum. The binding efficiency of (111)In-DTPA-rFVIIa to TF (1-209)-sepharose was 48% in buffer whereas 39%-36% in serum, respectively. In vivo experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6-1.8 MBq (111)In-DTPA-rFVIIa up to 120-130 min. Five min after administration of (111)In-DTPA-rFVIIa, percentage of (111)In activity was 6.0% in the cardiac region and 24.5% in the liver region. After 2 hours activity was decreased to 3.3% in heart while it had increased to 42.0% in the liver. The (111)In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with significant TF expression such as acute bleeding lesions in the gastrointestinal tract.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE"><PMID Version="1">22518302</PMID><DateCreated><Year>2012</Year><Month>04</Month><Day>20</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2090-1720</ISSN><JournalIssue CitedMedium="Internet"><Volume>2012</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>International journal of molecular imaging</Title><ISOAbbreviation>Int J Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.</ArticleTitle><Pagination><MedlinePgn>464810</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2012/464810</ELocationID><Abstract><AbstractText>The aim of this study is to investigate whether (111)Indium-labelled recombinant FVIIa (rFVIIa) could be a potential radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with (111)In chloride. In vitro binding efficiency of (111)In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buffer, while it was 88-82% in serum. The binding efficiency of (111)In-DTPA-rFVIIa to TF (1-209)-sepharose was 48% in buffer whereas 39%-36% in serum, respectively. In vivo experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6-1.8 MBq (111)In-DTPA-rFVIIa up to 120-130 min. Five min after administration of (111)In-DTPA-rFVIIa, percentage of (111)In activity was 6.0% in the cardiac region and 24.5% in the liver region. After 2 hours activity was decreased to 3.3% in heart while it had increased to 42.0% in the liver. The (111)In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with significant TF expression such as acute bleeding lesions in the gastrointestinal tract.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nalla</LastName><ForeName>Amarnadh</ForeName><Initials>A</Initials><Affiliation>Institute of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark.</Affiliation></Author><Author ValidYN="Y"><LastName>Buch</LastName><ForeName>Inge</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sigvardt</LastName><ForeName>Maibritt</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bodholdt</LastName><ForeName>Rasmus Poul</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Kjaer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hesse</LastName><ForeName>Birger</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>Int J Mol Imaging</MedlineTA><NlmUniqueID>101553817</NlmUniqueID><ISSNLinking>2090-1720</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1979 Oct;20(10):1080-6</RefSource><PMID Version="1">317093</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1994 May;35(5):882-9</RefSource><PMID Version="1">8176477</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8205-9</RefSource><PMID Version="1">7667269</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood Coagul Fibrinolysis. 2000 Apr;11(3):255-9</RefSource><PMID Version="1">10870806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2001 Apr;7(4):1061-72</RefSource><PMID Version="1">11309358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 2001 Jul;86(1):66-74</RefSource><PMID Version="1">11487043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2002 Oct;8(10):1175-81</RefSource><PMID Version="1">12244306</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haemophilia. 2004 Jul;10(4):352-9</RefSource><PMID Version="1">15230949</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2011 Apr 26;104(9):1401-9</RefSource><PMID Version="1">21427724</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Gynecol Cancer. 2011 May;21(4):616-24</RefSource><PMID Version="1">21543928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tumour Biol. 2011 Oct;32(5):921-30</RefSource><PMID Version="1">21625939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2011;11:263</RefSource><PMID Version="1">21693061</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Metastasis. 2011 Oct;28(7):689-700</RefSource><PMID Version="1">21725665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Radiopharm. 2011 Jan;4(1):1-4</RefSource><PMID Version="1">22191609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med. 1989;15(6):307-12</RefSource><PMID Version="1">2767080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1987 May;28(5):861-70</RefSource><PMID Version="1">3106595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1984 Oct;101(4):538-45</RefSource><PMID Version="1">6383166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1983 May 6;220(4597):613-5</RefSource><PMID Version="1">6836304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 1993 Sep 1;70(3):458-64</RefSource><PMID Version="1">8259549</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 1998 Dec;80(6):912-8</RefSource><PMID Version="1">9869160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Biochem Biophys. 1999 Mar 1;363(1):43-54</RefSource><PMID Version="1">10079116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haemostasis. 1998 Mar-Apr;28(2):93-8</RefSource><PMID Version="1">10087434</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1999 Dec 1;94(11):3951-3</RefSource><PMID Version="1">10572113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Echocardiogr. 2000 Jun;13(6):608-14</RefSource><PMID Version="1">10849515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2001 Jun;86(6):640-5</RefSource><PMID Version="1">11418374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 2001 Jul;86(1):334-45</RefSource><PMID Version="1">11487022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Hematol. 2002 Sep;9(5):401-6</RefSource><PMID Version="1">12172458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 May 1;103(9):3374-80</RefSource><PMID Version="1">14739228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Sci. 2004 Apr;21(5):597-606</RefSource><PMID Version="1">15066660</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Mol Med. 2005 Jan;15(1):129-35</RefSource><PMID Version="1">15583839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pathophysiol Haemost Thromb. 2006;35(1-2):103-10</RefSource><PMID Version="1">16855354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thromb Haemost. 2007 Mar;97(3):464-70</RefSource><PMID Version="1">17334515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Protoc. 2006;1(1):314-7</RefSource><PMID Version="1">17406251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Oct 10;27(29):4834-8</RefSource><PMID Version="1">19738116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Gastroenterol. 2011 Feb;45(2):92-9</RefSource><PMID Version="1">20861799</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Drug Target. 2008 Apr;16(3):185-97</RefSource><PMID Version="1">18365880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pathophysiol Haemost Thromb. 2008;36(3-4):160-76</RefSource><PMID Version="1">19176989</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med. 1988;13(11):598-604</RefSource><PMID Version="1">3350036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Nucl Med Biol. 1985;12(3):159-66</RefSource><PMID Version="1">4066196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1983 Dec;24(12):1158-63</RefSource><PMID Version="1">6644376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 1980 Feb;5(2):55-60</RefSource><PMID Version="1">6965471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Appl Radiat Isot. 1982 May;33(5):327-32</RefSource><PMID Version="1">7095875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 1991 Nov;64(5):850-6</RefSource><PMID Version="1">1931605</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">PMC3299322</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="epublish"><Year>2012</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1155/2012/464810</ArticleId><ArticleId IdType="pubmed">22518302</ArticleId><ArticleId IdType="pmc">PMC3299322</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001023 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001023 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22518302
|texte= (111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22518302" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |